elliptinium has been researched along with 9-hydroxyellipticine in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Archer, S; el-Hamouly, W; Modi, SP; Portuese, E; Ruckdeschel, JC | 1 |
| Auclair, C; Hyland, K; Paoletti, C | 1 |
| Denny, WA; Feigon, J; Kearns, DR; Leupin, W | 1 |
| Auclair, C; Paoletti, C | 1 |
| Auclair, C; Dubreuil, P; Le Bret, M; Letard, S; Martin, F; Svinarchuk, F; Vendôme, J | 1 |
| Laneelle, G; Lempereur, L; Sautereau, AM; Tocanne, JF | 1 |
| Capranico, G; Mabilia, M; Palumbo, M; Pozzan, A; Tinelli, S; Zunino, F | 1 |
| Jacquemin-Sablon, A; Jacquemin-Sablon, H; Khélifa, T; Lambert, B; Le Mée, S; Markovits, J; René, B; Saucier, JM | 1 |
8 other study(ies) available for elliptinium and 9-hydroxyellipticine
| Article | Year |
|---|---|
N-methylcarbamate derivatives of ellipticine and olivacine with cytotoxic activity against four human lung cancer cell lines.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carbamates; Ellipticines; Humans; Leukemia L1210; Lung Neoplasms; Mice; Structure-Activity Relationship; Tumor Cells, Cultured | 1992 |
Autoxidation of the antitumor drug 9-hydroxyellipticine and its derivatives.
Topics: Alkaloids; Chemical Phenomena; Chemistry; Edetic Acid; Ellipticines; Kinetics; Manganese; Oxidation-Reduction; Oxygen Consumption; Spectrophotometry; Structure-Activity Relationship; Superoxide Dismutase | 1983 |
Interactions of antitumor drugs with natural DNA: 1H NMR study of binding mode and kinetics.
Topics: Antineoplastic Agents; Base Composition; Chemical Phenomena; Chemistry; DNA; Hydrogen Bonding; Intercalating Agents; Kinetics; Magnetic Resonance Spectroscopy; Structure-Activity Relationship | 1984 |
Bioactivation of the antitumor drugs 9-hydroxyellipticine and derivatives by a peroxidase-hydrogen peroxide system.
Topics: Alkaloids; Animals; Antineoplastic Agents; Biotransformation; Ellipticines; Hydrogen Peroxide; Mice; Oxidation-Reduction; Peroxidases; Structure-Activity Relationship | 1981 |
Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases.
Topics: Adenosine Triphosphate; Binding, Competitive; Ellipticines; Mutation; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit | 2005 |
Ellipticine derivatives interacting with model membranes. Influence of quaternarization of nitrogen-2.
Topics: Alkaloids; Cations; Cell Membrane; Diffusion; Ellipticines; Liposomes; Phosphatidylglycerols; Spectrometry, Fluorescence; Structure-Activity Relationship | 1984 |
Conformational properties of topoisomerase II inhibitors and sequence specificity of DNA cleavage.
Topics: Base Sequence; DNA; DNA Topoisomerases, Type II; Ellipticines; Genistein; Isoflavones; Molecular Structure; Substrate Specificity; Topoisomerase II Inhibitors | 1994 |
Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Topics: Amsacrine; Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Cell Line; Cell Nucleus; Cell Survival; Cricetinae; Cricetulus; DNA Probes; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Complementary; DNA, Kinetoplast; Drug Resistance; Ellipticines; Etoposide; Fibroblasts; Humans; Isoenzymes; Phenotype; Point Mutation; Polymerase Chain Reaction; Polymorphism, Genetic; Recombinant Proteins; Transcription, Genetic; Transfection | 1999 |